Researchers from Universite de Sherbrooke and University of California San Francisco presented the discovery and preclinical characterization of CCR2-targeting pepducin, PP-101.
University of Copenhagen has described cyclic peptides acting as postsynaptic density-95 (PSD-95) protein inhibitors reported to be useful for the treatment of neuropathic pain.
Several Grünenthal GmbH patents describe sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers potentially useful for the treatment of pain.
Oblique Therapeutics AB has entered into an agreement with the KTH Royal Institute of Technology to utilize KTH’s supercomputer resources for analyzing protein structures.
Humanwell Healthcare (Group) Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), also known as PIP2, is a cellular membrane phospholipid generated by phosphatidylinositol phosphorylation that regulates the functions of several proteins.
News out of the Heart Rhythm Society 2024 meeting May 16-19 highlighted the rapid disruption pulsed field ablation (PFA) devices have wrought in cardiac arrhythmia treatment, so it is little surprise to see that PFAs are among the top five technologies with transformative potential identified by Clarivate plc in its Medical Technologies to Watch in 2024 report. The impact of the other four – continuous glucose monitors (CGM) for diabetes, neurostimulation devices, surgical robotics and renal denervation – has been just as revolutionary, if longer in being realized.
News out of the Heart Rhythm Society 2024 meeting May 16-19 highlighted the rapid disruption pulsed field ablation (PFA) devices have wrought in cardiac arrhythmia treatment, so it is little surprise to see that PFAs are among the top five technologies with transformative potential identified by Clarivate plc in its Medical Technologies to Watch in 2024 report. The impact of the other four – continuous glucose monitors (CGM) for diabetes, neurostimulation devices, surgical robotics and renal denervation – has been just as revolutionary, if longer in being realized.
Adolore Biotherapeutics Inc. has offered an update on recent pipeline development progress as it advances nonopioid analgesic gene therapies for the treatment of chronic pain.
Brixton Biosciences Inc. closed a $33 million series B funding round that it plans to immediately use to pursue two clinical trials to evaluate the use of its Neural Ice nerve block for knee pain. The injectable product received U.S. FDA breakthrough device designation in October.
